BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:zelicapavir readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of zelicapavir\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07482657-10790@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:zelicapavir: Phase 2 readout est. (NCT07482657)
DESCRIPTION:zelicapavir\, phase 2.\nStudy: A Phase 2 Study to Investigate t
 he Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to 
 ≤36 Months of Age Infected With Respiratory Syncytial Virus\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zelicapavir#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07482657
URL:https://assetmemo.bio/drug/zelicapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908381-10790@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:zelicapavir: Phase 2/3 readout est. (NCT07908381)
DESCRIPTION:zelicapavir\, phase 2/3.\nStudy: A Study to Investigate the Eff
 icacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV W
 ho Are at High Risk for Severe Disease\nEstimated primary completion: July
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zelicapavir#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079083
 81
URL:https://assetmemo.bio/drug/zelicapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
